Fulgent Genetics, Inc.
Fulgent Genetics, Inc. Fundamental Analysis
Fulgent Genetics, Inc. (FLGT) shows weak financial fundamentals with a PE ratio of -16.45, profit margin of -13.62%, and ROE of -3.82%. The company generates $0.3B in annual revenue with weak year-over-year growth of -1.99%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 12.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze FLGT's fundamental strength across five key dimensions:
Efficiency Score
WeakFLGT struggles to generate sufficient returns from assets.
Valuation Score
ExcellentFLGT trades at attractive valuation levels.
Growth Score
ModerateFLGT shows steady but slowing expansion.
Financial Health Score
ExcellentFLGT maintains a strong and stable balance sheet.
Profitability Score
WeakFLGT struggles to sustain strong margins.
Key Financial Metrics
Is FLGT Expensive or Cheap?
P/E Ratio
FLGT trades at -16.45 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, FLGT's PEG of -1.01 indicates potential undervaluation.
Price to Book
The market values Fulgent Genetics, Inc. at 0.63 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -26.26 times EBITDA. This is generally considered low.
How Well Does FLGT Make Money?
Net Profit Margin
For every $100 in sales, Fulgent Genetics, Inc. keeps $-13.62 as profit after all expenses.
Operating Margin
Core operations generate -22.50 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-3.82 in profit for every $100 of shareholder equity.
ROA
Fulgent Genetics, Inc. generates $-3.54 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Fulgent Genetics, Inc. generates limited operating cash flow of $1.53M, signaling weaker underlying cash strength.
Free Cash Flow
Fulgent Genetics, Inc. generates weak or negative free cash flow of $-19.95M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.65 in free cash annually.
FCF Yield
FLGT converts -2.79% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-16.45
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.63
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.25
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.007
vs 25 benchmark
Current Ratio
Current assets to current liabilities
7.005
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.04
vs 25 benchmark
ROA
Return on assets percentage
-0.04
vs 25 benchmark
ROCE
Return on capital employed
-0.06
vs 25 benchmark
How FLGT Stacks Against Its Sector Peers
| Metric | FLGT Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -16.45 | 29.28 | Better (Cheaper) |
| ROE | -3.82% | 820.00% | Weak |
| Net Margin | -13.62% | -19731.00% (disorted) | Weak |
| Debt/Equity | 0.01 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 7.01 | 4.69 | Strong Liquidity |
| ROA | -3.54% | -17993.00% (disorted) | Weak |
FLGT outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Fulgent Genetics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
439.25%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-6329.96%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
136.21%
Industry Style: Defensive, Growth, Innovation
High Growth